Regencell Bioscience Holdings Ltd (RGC) Cash Flow Statement
Regencell Bioscience Holdings Ltd (RGC) generated -$7.7M of operating cash flow over the twelve months to its latest filing, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · read by EquiReason
RGCRegencell Bioscience Holdings LtdFollow RGC — free
—
Price chart with a free account
- Market cap
- 3.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
| Line | FY2021 Jun 21 | FY2022 Jun 22 | FY2023 Jun 23 | FY2024 Jun 24 | FY2025 Jun 25 | FY2026 Jun 26 | TTM | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.8 | -5.3 | -5.0 | -4.0 | -3.1 | -7.7 | -7.7 | |
| Capital expenditure | — | 0.8 | 0.0 | 0.0 | 0.2 | — | — | |
| Free cash flow | — | -6.0 | -5.0 | -4.0 | -3.3 | — | — | |
| Stock-based compensation | — | 2.8 | 0.9 | 0.4 | 0.2 | 3.2 | — |
USD millions · SEC XBRL
Regencell Bioscience Holdings Ltd — questions
- What is Regencell Bioscience Holdings Ltd's operating cash flow?
- -$7.7M over the twelve months to the latest filing.
Every figure on this page comes from Regencell Bioscience Holdings Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.